Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Oncogenomics Stories

2014-04-07 16:10:23

A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment. Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive. Now, researchers at the Stanford University School of Medicine have devised a way to quickly bring...

2014-01-30 23:03:55

In the second whole-genome sequencing study ever conducted in bladder cancer, a Roswell Park-led team observed two distinct patterns of aberrations, and identified a potential target for therapy. Buffalo, NY (PRWEB) January 30, 2014 In the first whole-genome analysis conducted through the Roswell Park Cancer Institute (RPCI) Center for Personalized Medicine, researchers report that invasive bladder cancers demonstrate two distinct patterns of genetic alteration, one of which may result...

Cancer Genomics Knowledge Expanded By Broad Institute Researchers
2014-01-26 06:09:02

April Flowers for redOrbit.com - Your Universe Online A research team led by the Broad Institute has released the findings of a landmark study across many cancer types. The findings, published in Nature, reveal that the universe of cancer mutations is much bigger than scientists previously thought. For their study, the team analyzed the genomes of thousands of patients' tumors, which allowed them to expand the list of known genes tied to these cancers by 25 percent. The study also...

2013-12-18 11:26:28

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients. “When you have known oncogenes that are already targeted by FDA-approved drugs, it just made sense...

Genetic Mutation Promotes One Percent Of Cancerous Tumors
2013-12-09 05:28:31

[ Watch the Video: CUX1: Cancer’s Common Ground ] redOrbit Staff & Wire Reports - Your Universe Online Scientists have located a single gene that is at least partially responsible for the development of one percent of all cancerous tumors, according to new research appearing in the advanced online edition of the journal Nature Genetics. The gene in question is CUX1, and according to the study authors, this is the first time it has been broadly associated with the onset of...

2013-10-15 13:09:14

Computer scientists worked with doctors to develop new treatment that would kill cancer cells but spare healthy cells Researchers from the University of Minnesota, Mayo Clinic, and University of Toronto have successfully shown that a new method for targeting mutated cells could create a major breakthrough in a personalized medicine approach to treat cancer. The team’s findings are published in the Oct. 15 issue of Cancer Research, a journal of the American Association of Cancer...

2013-10-14 11:16:07

Researchers at Washington University School of Medicine in St. Louis have created a massive online database that matches thousands of genes linked to cancer and other diseases with drugs that target those genes. Some of the drugs are approved by the U.S. Food and Drug Administration, while others are in clinical trials or just entering the drug development pipeline. The database was developed by identical twin brothers, Obi Griffith, PhD, and Malachi Griffith, PhD, whose interest in...

2013-09-10 08:30:08

WHIPPANY, N.J., Sept. 10, 2013 /PRNewswire/ -- Bayer HealthCare has entered into a strategic alliance with the Broad Institute in Cambridge, Massachusetts in the area of oncogenomics and drug discovery. The Broad Institute, one of the world's most renowned non-profit biomedical research institutes, brings together scientists from Harvard, MIT and the Harvard-affiliated hospitals, and has deep expertise in genomics, cancer, chemical biology, and drug discovery, as well as other areas....

2013-09-09 20:30:18

While great strides have been achieved in cancer treatment, scientists are looking for the new targets and next generation of therapeutics to stop this second leading cause of death nationwide. A new platform for drug discovery has been developed through a collaborative effort linking chemists at NYU and pharmacologists at USC. In a study appearing in Proceedings of the National Academy of Sciences, the research groups of Paramjit Arora, a professor in NYU's Department of Chemistry, and...

2013-09-06 04:20:26

Study to investigate Trovagene's non-invasive cancer monitoring technology using cell-free DNA from urine samples SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of molecular diagnostics for cancer monitoring, today announced that the Company has entered into a clinical collaboration agreement with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using Trovagene's proprietary cell-free DNA...